Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16032766 | 0.82 | HDAC1 (0.48) | SMN1; SMN2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL29065959 | 0.82 | XDH (0.48) | MAPTALDH1A1KDM4EHDAC3HDAC4 | |
| SCHEMBL1314645 | 0.82 | PTPN11 (0.43) | SMN1; SMN2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL9394 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2MAPTNPC1RAB9APPARG | |
| SCHEMBL29183399 | 0.81 | ALDH1A1 (0.39) | SMN1; SMN2MAPTALDH1A1KDM4EKMT2A | |
| SCHEMBL23146389 | 0.80 | CDC7 (0.45) | MAPTALDH1A1HPGDKDM4EHDAC3 | |
| SCHEMBL1849553 | 0.78 | GAA (0.45) | SMN1; SMN2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL12151093 | 0.78 | NPC1 (0.40) | SMN1; SMN2MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL23146302 | 0.78 | KDM4E (0.45) | SMN1; SMN2MAPTNPC1RAB9ANFKB1 | |
| SCHEMBL8336785 | 0.78 | KMO (0.37) | MAPTNPC1RAB9AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117285524-A | Substituted 4-amino isoindoline compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-12-26 | — | — | CN | disclosed |
| WO-2019104011-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| CN-102471311-B | The ring diketone or derivatives thereof of the heteroaryl replacement of weeding activity | SYNGENTA LTD. (GB) | 2016-04-27 | — | — | CN | disclosed |
| EP-2459547-B1 | HERBICIDALLY ACTIVE HETEROARYL-SUBSTITUTED CYCLIC DIONES OR DERIVATIVES THEREOF | SYNGENTA LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2459547-B1 | HERBICIDALLY ACTIVE HETEROARYL-SUBSTITUTED CYCLIC DIONES OR DERIVATIVES THEREOF | SYNGENTA LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| CN-102459202-B | As the inhibitor isoxazoline of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-9051300-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-9051300-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-9051300-B2 | Herbicides | SYNGENTA LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| EP-2375899-B1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES | ARRAY BIOPHARMA INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2173727-A1 | NOVEL HERBICIDES | Syngenta Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009000533-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| EP-1592421-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1572691-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-20050004200-A1 | Pyrazole compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-06 | — | — | US | disclosed |
| WO-2004058761-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058761-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043344-A1 | Heteroarylalkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGAV, ITGA6 | SMN1; SMN2 4308/4885MAPT 4206/4885NPC1 983/4885 |
| US-20050004200-A1 | Pyrazole compounds as integrin receptor antagonists derivatives | ITGA5, ITGB3, ITGB5 | SMN1; SMN2 4365/4885MAPT 3391/4885NPC1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.